High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave lithotripsy and ultrasonic propulsion may offer future office-based alternatives to traditional surgical stone management.
Daniel George, MD, discusses key efficacy findings from the phase 3 CAPItello-281 trial evaluating capivasertib plus abiraterone vs placebo plus abiraterone in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Alexandra Drakaki, MD, discusses guidance from a modified Delphi panel on managing peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin.
David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient comfort.
Giulia Almiron da R. Soares discusses survey findings examining the factors influencing women’s decisions to pursue careers in urology.
Christopher M. Pieczonka, MD, discusses practical strategies to optimize tolerability and minimize early discontinuation with indwelling intravesical drug-releasing systems for bladder cancer.
Hugo's 7-degree-of-freedom instrumentation, power-based electrosurgical architecture, and visual haptic feedback support precise reconstructive performance, while the platform's strong IDE trial outcomes are attributed to a proficiency-based progression training model that assesses both surgeons and operative teams before independent practice.
Matthias Saar, MD, discusses findings from the phase 2 INDUCTA study, evaluating the use of inductive hormonal therapy to achieve operability in patients with T4 prostate cancer.
Despite promising candidates across tumor, immune, and systemic marker categories, no biomarker yet reliably predicts BCG response or identifies which NMIBC patients would benefit from adding checkpoint inhibitor therapy—a gap that limits informed shared decision-making and broader adoption of IO-BCG combinations despite positive trial data.
Meri-Margaret Deoudes discusses findings from the Bladder Cancer Advocacy Network’s "New Faces of Bladder Cancer" survey.
Daniel Shapiro, MD, FACS, discusses how emerging biomarker strategies and evolving combination therapies are reshaping risk stratification and treatment decision-making in kidney cancer.
Anjali Kapur, MD, discusses a post-market analysis of the safety of the eCoin implantable tibial nerve stimulator for patients with urge urinary incontinence.
Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer.
Bogdana Schmidt, MD, MPH, identified several subgroups most likely to harbor occult systemic disease and therefore potentially benefit from adding immunotherapy to BCG:
Matthew D. Galsky, MD, discusses the mechanism of action for FX-909, a first-in-class agent targeting PPARγ in advanced urothelial carcinoma.
The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.
Data from the CLIMATE trial indicate that detectable miR-371 post-orchiectomy is a marker of MRD in patients with clinical stage 1 testicular germ cell tumor.
The Hugo RAS system requires wider, offset port placement compared to conventional platforms, and its open console design promotes a more ergonomically sound upright posture that may reduce the cervical spine strain associated with prolonged use of immersive closed-console robotic systems.
Christopher M. Pieczonka, MD, discusses the design and interim findings from the phase 2 QUILT 2.005 trial.
Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.
Sara Coca Membribes, MD, highlights several emerging therapeutic strategies with near-term clinical implications.
Mark Farha, MD, BSc, MBA, discusses the development of a novel genomic score designed to predict early BCG failure in patients with non–muscle invasive bladder cancer.
According to Chew, Break Wave lithotripsy is best suited to renal and ureterovesical junction stones, where ultrasound visualization is most reliable.
Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.
At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.
On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.
Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.
Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.
On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.
On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.
